234 related articles for article (PubMed ID: 12908513)
21. [Costs of pneumococcal infections and cost evaluation of heptavalent conjugate vaccine].
D'Alessandro D
Ann Ig; 2002; 14(6 Suppl 7):43-8. PubMed ID: 12638364
[TBL] [Abstract][Full Text] [Related]
22. Invasive pneumococcal disease and the need for the new 13-valent pneumococcal vaccine.
Bolton M; Barson W
Pediatr Ann; 2010 Aug; 39(8):497-503. PubMed ID: 20704146
[No Abstract] [Full Text] [Related]
23. Cost-effectiveness studies of pneumococcal conjugate vaccines.
McIntosh ED
Expert Rev Vaccines; 2004 Aug; 3(4):433-42. PubMed ID: 15270648
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
Marchetti M; Colombo GL
Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
[TBL] [Abstract][Full Text] [Related]
25. Prevnar(tm): a pneumococcal conjugate vaccine for infants and young children.
Brown A
Issues Emerg Health Technol; 2001 Feb; (14):1-6. PubMed ID: 11902222
[No Abstract] [Full Text] [Related]
26. Vaccines for other neonatal infections: pneumococcal disease: a major global health problem of young children.
Richmond P
Expert Rev Vaccines; 2004 Aug; 3(4):379-82. PubMed ID: 15270639
[TBL] [Abstract][Full Text] [Related]
27. Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.
Paradiso P
Vaccine; 2009 Aug; 27 Suppl 3():C15-8. PubMed ID: 19683657
[TBL] [Abstract][Full Text] [Related]
28. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
[TBL] [Abstract][Full Text] [Related]
29. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
[TBL] [Abstract][Full Text] [Related]
30. Serotype coverage of invasive and mucosal pneumococcal disease in Israeli children younger than 3 years by various pneumococcal conjugate vaccines.
Shouval DS; Greenberg D; Givon-Lavi N; Porat N; Dagan R
Pediatr Infect Dis J; 2009 Apr; 28(4):277-82. PubMed ID: 19258924
[TBL] [Abstract][Full Text] [Related]
31. Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe.
Reinert RR; Paradiso P; Fritzell B
Expert Rev Vaccines; 2010 Mar; 9(3):229-36. PubMed ID: 20218848
[No Abstract] [Full Text] [Related]
32. Heptavalent pneumococcal conjugate vaccine: current and future impact.
Hsu KK; Pelton SI
Expert Rev Vaccines; 2003 Oct; 2(5):619-31. PubMed ID: 14711324
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis.
Pavia M; Bianco A; Nobile CG; Marinelli P; Angelillo IF
Pediatrics; 2009 Jun; 123(6):e1103-10. PubMed ID: 19482744
[TBL] [Abstract][Full Text] [Related]
34. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
[TBL] [Abstract][Full Text] [Related]
36. Authors' reply to Prymula R. Re: "Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines" [Vaccine 27 (2009) 4739-4740].
Rodgers GL; Arguedas A; Cohen R; Dagan R
Vaccine; 2009 Sep; 27(40):5429-30. PubMed ID: 19643215
[No Abstract] [Full Text] [Related]
37. Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.
Grijalva CG; Griffin MR
Expert Rev Vaccines; 2008 Feb; 7(1):83-95. PubMed ID: 18251696
[TBL] [Abstract][Full Text] [Related]
38. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain).
Navas E; Salleras L; Gisbert R; Domínguez A; Timoner E; Ibáñez D; Prat A
Vaccine; 2005 Mar; 23(17-18):2342-8. PubMed ID: 15755625
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
40. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada.
Feavers I; Knezevic I; Powell M; Griffiths E;
Vaccine; 2009 Jun; 27(28):3681-8. PubMed ID: 19442421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
